Mechanisms in CME

CME Module Index

Module 1: Biology and Pathophysiology of Chronic Myelogenous Leukemia Module 1: Biology and Pathophysiology of Chronic Myelogenous Leukemia

Chronic myelogenous leukemia (CML) is a myeloproliferative disease characterized by the presence of a specific cytogenetic abnormality, the Philadelphia (Ph) chromosome

CME Credits
2.00 AMA PRA
Category 1 Credits™

Module 2: Clinical Manifestations and Laboratory Studies Module 2: Clinical Manifestations and Laboratory Studies

Of the nearly 5000 cases of CML diagnosed each year, approximately 90% of patients are diagnosed in the chronic phase (CP)

CME Credits
1.50 AMA PRA
Category 1 Credits™

Module 3: Current Treatment of Chronic Myelogenous Leukemia – Imatinib and Allogeneic SCT Module 3: Current Treatment of Chronic Myelogenous Leukemia – Imatinib and Allogeneic SCT

Over the course of the last several years, imatinib mesylate, a tyrosine kinase inhibitor, has dramatically altered the treatment of chronic myelogenous leukemia (CML)

CME Credits
1.00 AMA PRA
Category 1 Credits™

Module 4: Mechanisms of Resistance Module 4: Mechanisms of Resistance

Primary resistance is defined as the failure of a patient to attain a predefined level of response, eg, a complete hematologic response (CHR) or CCyR

CME Credits
2.50 AMA PRA
Category 1 Credits™

Module 5: Treatment of Imatinib Resistant Chronic Myelogenous Leukemia Module 5: Treatment of Imatinib Resistant Chronic Myelogenous Leukemia

Chronic myelogenous leukemia was the first neoplastic disease for which a direct chromosomal link was identified

CME Credits
1.50 AMA PRA
Category 1 Credits™

Module 6: Monitoring of Treatment of Chronic Myelogenous Leukemia Module 6: Monitoring of Treatment of Chronic Myelogenous Leukemia

Chronic myelogenous leukemia (CML) constitutes a clinical model for molecular detection and monitoring for disease progression and therapeutic efficacy

CME Credits
2.00 AMA PRA
Category 1 Credits™

Module 7: Chronic Myelogenous Leukemia Treatment Guidelines Module 7: Chronic Myelogenous Leukemia Treatment Guidelines

Treatment guidelines in CML focus on patients for whom imatinib therapy has failed. A number of studies suggest, however, that earlier responses to imatinib therapy

CME Credits
1.00 AMA PRA
Category 1 Credits™

Module 8: Questions on Management and Treatment: Side Effects and Drug Interactions Module 8: Questions on Management and Treatment: Side Effects and Drug Interactions

The introduction of imatinib has marked an important and revolutionary step in the management of chronic myelogenous leukemia (CML)

CME Credits
1.50 AMA PRA
Category 1 Credits™